| 20097180 |
Kim JY, Lee WK, Yu YG, Kim JH: Blockade of LTB (4)-induced chemotaxis by bioactive molecules interfering with the BLT2-Galpha (i) interaction. Biochem Pharmacol. 2010 May 15;79(10):1506-15. Epub 2010 Jan 25.
BLT2, a low-affinity leukotriene B (4) (LTB (4)) receptor, is a member of the G-protein coupled receptor (GPCR) family and is involved in the pathogenesis of inflammatory diseases such as asthma. Despite its clinical implications, however, no pharmacological inhibitors are available. In the present study, we screened for small molecules that interfere with the interaction between the third intracellular loop region of BLT2 (BLT2 (iL3)) and the Galpha (i3) protein subunit (Galpha (i3)), using a high-throughput screening (HTS) assay with a library of 1040 FDA-approved drugs and bioactive compounds. We identified two small molecules-purpurin [1,2,4-trihydroxy-9,10-anthraquinone; IC (50)=1.6 microM for BLT2] and chloranil [tetrachloro-1,4-benzoquinone; IC (50)=0.42 microM for BLT2]-as specific BLT2-blocking agents. We found that blockade of the BLT2 (iL3)-Galpha (i3) interaction by these small molecules inhibited the BLT2-downstream signaling cascade. For example, BLT2-signaling to phosphoinositide-3 kinase (PI3K)/Akt phosphorylation was completely abolished by these molecules. Furthermore, we observed that these small molecules blocked LTB (4)-induced chemotaxis by inhibiting the BLT2-PI3K/Akt-downstream, Rac1-reactive oxygen species-dependent pathway. Taken together, our results show that purpurin and chloranil interfere with the interaction between BLT2 (iL3) and Galpha (i3) and thus block the biological functions of BLT2 (e.g., chemotaxis). The present findings suggest a potential application of purpurin and chloranil as pharmacological therapeutic agents against BLT2-associated inflammatory human diseases. |
39(0,1,1,9) |